aluates Reports

$ 0.0

Automative

Global Ibritumomab Tiuxetan Market Research Report 2024

Published Date: June 2024

Report Code: QYRE-Auto-15W12298

Global Ibritumomab Tiuxetan Market Research Report 2022

BUY CHAPTERS

Global Ibritumomab Tiuxetan Market Research Report 2024

Code: QYRE-Auto-15W12298

Report

June 2024

Pages:70

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

CASI Pharmaceuticals

Biogen

Bayer

Spectrum

CSL Behring

Grifols S A

Baxalta

Octapharma AG

Kedrion S p A

Ibritumomab Tiuxetan Market

It is the world's first radiolabeled monoclonal antibody, launched in the United States in 2002 and approved for the treatment of refractory and relapsed B-cell non-Hodgkin's lymphoma. Radioimmunization represented by Zevalin marks a new era for human treatment of non-Hodgkin lymphoma. Zevalin combines the excellent targeting of monoclonal antibodies and the powerful radiotherapy effect of radioisotopes, so it can maximize the effect of radiotherapy. kill tumor cells.

The global Ibritumomab Tiuxetan market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Ibritumomab Tiuxetan in Follicular Non-hodgkin Lymphoma is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Ibritumomab Tiuxetan include CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma and Kedrion, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Ibritumomab Tiuxetan, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ibritumomab Tiuxetan.

Report Scope

The Ibritumomab Tiuxetan market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ibritumomab Tiuxetan market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Ibritumomab Tiuxetan companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Ibritumomab Tiuxetan Market Report

Report Metric	Details
Report Name	Ibritumomab Tiuxetan Market
Segment by Type	0.05 0.25
Segment by Application	Follicular Non-hodgkin Lymphoma Metastatic B-cell Non-hodgkin Lymphoma
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma, Kedrion
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ibritumomab Tiuxetan companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Ibritumomab Tiuxetan Market report?

Ans: The main players in the Ibritumomab Tiuxetan Market are CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma, Kedrion

What are the Application segmentation covered in the Ibritumomab Tiuxetan Market report?

Ans: The Applications covered in the Ibritumomab Tiuxetan Market report are Follicular Non-hodgkin Lymphoma, Metastatic B-cell Non-hodgkin Lymphoma

What are the Type segmentation covered in the Ibritumomab Tiuxetan Market report?

Ans: The Types covered in the Ibritumomab Tiuxetan Market report are 0.05, 0.25

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Ibritumomab Tiuxetan Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 0.05

1.2.3 0.25

1.3 Market by Application

1.3.1 Global Ibritumomab Tiuxetan Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Follicular Non-hodgkin Lymphoma

1.3.3 Metastatic B-cell Non-hodgkin Lymphoma

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Ibritumomab Tiuxetan Market Perspective (2019-2030)

2.2 Ibritumomab Tiuxetan Growth Trends by Region

2.2.1 Global Ibritumomab Tiuxetan Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Ibritumomab Tiuxetan Historic Market Size by Region (2019-2024)

2.2.3 Ibritumomab Tiuxetan Forecasted Market Size by Region (2025-2030)

2.3 Ibritumomab Tiuxetan Market Dynamics

2.3.1 Ibritumomab Tiuxetan Industry Trends

2.3.2 Ibritumomab Tiuxetan Market Drivers

2.3.3 Ibritumomab Tiuxetan Market Challenges

2.3.4 Ibritumomab Tiuxetan Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Ibritumomab Tiuxetan Players by Revenue

3.1.1 Global Top Ibritumomab Tiuxetan Players by Revenue (2019-2024)

3.1.2 Global Ibritumomab Tiuxetan Revenue Market Share by Players (2019-2024)

3.2 Global Ibritumomab Tiuxetan Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Ibritumomab Tiuxetan Revenue

3.4 Global Ibritumomab Tiuxetan Market Concentration Ratio

3.4.1 Global Ibritumomab Tiuxetan Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Ibritumomab Tiuxetan Revenue in 2023

3.5 Ibritumomab Tiuxetan Key Players Head office and Area Served

3.6 Key Players Ibritumomab Tiuxetan Product Solution and Service

3.7 Date of Enter into Ibritumomab Tiuxetan Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Ibritumomab Tiuxetan Breakdown Data by Type

4.1 Global Ibritumomab Tiuxetan Historic Market Size by Type (2019-2024)

4.2 Global Ibritumomab Tiuxetan Forecasted Market Size by Type (2025-2030)

5 Ibritumomab Tiuxetan Breakdown Data by Application

5.1 Global Ibritumomab Tiuxetan Historic Market Size by Application (2019-2024)

5.2 Global Ibritumomab Tiuxetan Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Ibritumomab Tiuxetan Market Size (2019-2030)

6.2 North America Ibritumomab Tiuxetan Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Ibritumomab Tiuxetan Market Size by Country (2019-2024)

6.4 North America Ibritumomab Tiuxetan Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Ibritumomab Tiuxetan Market Size (2019-2030)

7.2 Europe Ibritumomab Tiuxetan Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Ibritumomab Tiuxetan Market Size by Country (2019-2024)

7.4 Europe Ibritumomab Tiuxetan Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Ibritumomab Tiuxetan Market Size (2019-2030)

8.2 Asia-Pacific Ibritumomab Tiuxetan Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Ibritumomab Tiuxetan Market Size by Region (2019-2024)

8.4 Asia-Pacific Ibritumomab Tiuxetan Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Ibritumomab Tiuxetan Market Size (2019-2030)

9.2 Latin America Ibritumomab Tiuxetan Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Ibritumomab Tiuxetan Market Size by Country (2019-2024)

9.4 Latin America Ibritumomab Tiuxetan Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Ibritumomab Tiuxetan Market Size (2019-2030)

10.2 Middle East & Africa Ibritumomab Tiuxetan Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2019-2024)

10.4 Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 CASI Pharmaceuticals

11.1.1 CASI Pharmaceuticals Company Detail

11.1.2 CASI Pharmaceuticals Business Overview

11.1.3 CASI Pharmaceuticals Ibritumomab Tiuxetan Introduction

11.1.4 CASI Pharmaceuticals Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.1.5 CASI Pharmaceuticals Recent Development

11.2 Biogen

11.2.1 Biogen Company Detail

11.2.2 Biogen Business Overview

11.2.3 Biogen Ibritumomab Tiuxetan Introduction

11.2.4 Biogen Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.2.5 Biogen Recent Development

11.3 Bayer

11.3.1 Bayer Company Detail

11.3.2 Bayer Business Overview

11.3.3 Bayer Ibritumomab Tiuxetan Introduction

11.3.4 Bayer Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.3.5 Bayer Recent Development

11.4 Spectrum

11.4.1 Spectrum Company Detail

11.4.2 Spectrum Business Overview

11.4.3 Spectrum Ibritumomab Tiuxetan Introduction

11.4.4 Spectrum Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.4.5 Spectrum Recent Development

11.5 CSL Behring

11.5.1 CSL Behring Company Detail

11.5.2 CSL Behring Business Overview

11.5.3 CSL Behring Ibritumomab Tiuxetan Introduction

11.5.4 CSL Behring Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.5.5 CSL Behring Recent Development

11.6 Grifols

11.6.1 Grifols Company Detail

11.6.2 Grifols Business Overview

11.6.3 Grifols Ibritumomab Tiuxetan Introduction

11.6.4 Grifols Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.6.5 Grifols Recent Development

11.7 Baxalta

11.7.1 Baxalta Company Detail

11.7.2 Baxalta Business Overview

11.7.3 Baxalta Ibritumomab Tiuxetan Introduction

11.7.4 Baxalta Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.7.5 Baxalta Recent Development

11.8 Octapharma

11.8.1 Octapharma Company Detail

11.8.2 Octapharma Business Overview

11.8.3 Octapharma Ibritumomab Tiuxetan Introduction

11.8.4 Octapharma Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.8.5 Octapharma Recent Development

11.9 Kedrion

11.9.1 Kedrion Company Detail

11.9.2 Kedrion Business Overview

11.9.3 Kedrion Ibritumomab Tiuxetan Introduction

11.9.4 Kedrion Revenue in Ibritumomab Tiuxetan Business (2019-2024)

11.9.5 Kedrion Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

CASI Pharmaceuticals

Biogen

Bayer

Spectrum

CSL Behring

Grifols S A

Baxalta

Octapharma AG

Kedrion S p A

List of Tables

Table 1. Global Ibritumomab Tiuxetan Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of 0.05

Table 3. Key Players of 0.25

Table 4. Global Ibritumomab Tiuxetan Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Ibritumomab Tiuxetan Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Ibritumomab Tiuxetan Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Ibritumomab Tiuxetan Market Share by Region (2019-2024)

Table 8. Global Ibritumomab Tiuxetan Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Ibritumomab Tiuxetan Market Share by Region (2025-2030)

Table 10. Ibritumomab Tiuxetan Market Trends

Table 11. Ibritumomab Tiuxetan Market Drivers

Table 12. Ibritumomab Tiuxetan Market Challenges

Table 13. Ibritumomab Tiuxetan Market Restraints

Table 14. Global Ibritumomab Tiuxetan Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Ibritumomab Tiuxetan Market Share by Players (2019-2024)

Table 16. Global Top Ibritumomab Tiuxetan Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ibritumomab Tiuxetan as of 2023)

Table 17. Ranking of Global Top Ibritumomab Tiuxetan Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Ibritumomab Tiuxetan Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Ibritumomab Tiuxetan Product Solution and Service

Table 21. Date of Enter into Ibritumomab Tiuxetan Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Ibritumomab Tiuxetan Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Ibritumomab Tiuxetan Revenue Market Share by Type (2019-2024)

Table 25. Global Ibritumomab Tiuxetan Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Ibritumomab Tiuxetan Revenue Market Share by Type (2025-2030)

Table 27. Global Ibritumomab Tiuxetan Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Ibritumomab Tiuxetan Revenue Market Share by Application (2019-2024)

Table 29. Global Ibritumomab Tiuxetan Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Ibritumomab Tiuxetan Revenue Market Share by Application (2025-2030)

Table 31. North America Ibritumomab Tiuxetan Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Ibritumomab Tiuxetan Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Ibritumomab Tiuxetan Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Ibritumomab Tiuxetan Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Ibritumomab Tiuxetan Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Ibritumomab Tiuxetan Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Ibritumomab Tiuxetan Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Ibritumomab Tiuxetan Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Ibritumomab Tiuxetan Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Ibritumomab Tiuxetan Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Ibritumomab Tiuxetan Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Ibritumomab Tiuxetan Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Ibritumomab Tiuxetan Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2025-2030) & (US$ Million)

Table 46. CASI Pharmaceuticals Company Detail

Table 47. CASI Pharmaceuticals Business Overview

Table 48. CASI Pharmaceuticals Ibritumomab Tiuxetan Product

Table 49. CASI Pharmaceuticals Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 50. CASI Pharmaceuticals Recent Development

Table 51. Biogen Company Detail

Table 52. Biogen Business Overview

Table 53. Biogen Ibritumomab Tiuxetan Product

Table 54. Biogen Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 55. Biogen Recent Development

Table 56. Bayer Company Detail

Table 57. Bayer Business Overview

Table 58. Bayer Ibritumomab Tiuxetan Product

Table 59. Bayer Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 60. Bayer Recent Development

Table 61. Spectrum Company Detail

Table 62. Spectrum Business Overview

Table 63. Spectrum Ibritumomab Tiuxetan Product

Table 64. Spectrum Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 65. Spectrum Recent Development

Table 66. CSL Behring Company Detail

Table 67. CSL Behring Business Overview

Table 68. CSL Behring Ibritumomab Tiuxetan Product

Table 69. CSL Behring Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 70. CSL Behring Recent Development

Table 71. Grifols Company Detail

Table 72. Grifols Business Overview

Table 73. Grifols Ibritumomab Tiuxetan Product

Table 74. Grifols Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 75. Grifols Recent Development

Table 76. Baxalta Company Detail

Table 77. Baxalta Business Overview

Table 78. Baxalta Ibritumomab Tiuxetan Product

Table 79. Baxalta Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 80. Baxalta Recent Development

Table 81. Octapharma Company Detail

Table 82. Octapharma Business Overview

Table 83. Octapharma Ibritumomab Tiuxetan Product

Table 84. Octapharma Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 85. Octapharma Recent Development

Table 86. Kedrion Company Detail

Table 87. Kedrion Business Overview

Table 88. Kedrion Ibritumomab Tiuxetan Product

Table 89. Kedrion Revenue in Ibritumomab Tiuxetan Business (2019-2024) & (US$ Million)

Table 90. Kedrion Recent Development

Table 91. Research Programs/Design for This Report

Table 92. Key Data Information from Secondary Sources

Table 93. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Ibritumomab Tiuxetan Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Ibritumomab Tiuxetan Market Share by Type: 2023 VS 2030

Figure 3. 0.05 Features

Figure 4. 0.25 Features

Figure 5. Global Ibritumomab Tiuxetan Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Ibritumomab Tiuxetan Market Share by Application: 2023 VS 2030

Figure 7. Follicular Non-hodgkin Lymphoma Case Studies

Figure 8. Metastatic B-cell Non-hodgkin Lymphoma Case Studies

Figure 9. Ibritumomab Tiuxetan Report Years Considered

Figure 10. Global Ibritumomab Tiuxetan Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 11. Global Ibritumomab Tiuxetan Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Ibritumomab Tiuxetan Market Share by Region: 2023 VS 2030

Figure 13. Global Ibritumomab Tiuxetan Market Share by Players in 2023

Figure 14. Global Top Ibritumomab Tiuxetan Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ibritumomab Tiuxetan as of 2023)

Figure 15. The Top 10 and 5 Players Market Share by Ibritumomab Tiuxetan Revenue in 2023

Figure 16. North America Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 17. North America Ibritumomab Tiuxetan Market Share by Country (2019-2030)

Figure 18. United States Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. Canada Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Europe Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Ibritumomab Tiuxetan Market Share by Country (2019-2030)

Figure 22. Germany Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. France Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. U.K. Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Italy Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Russia Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Nordic Countries Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Asia-Pacific Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Ibritumomab Tiuxetan Market Share by Region (2019-2030)

Figure 30. China Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Japan Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. South Korea Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Southeast Asia Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. India Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Australia Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Latin America Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Ibritumomab Tiuxetan Market Share by Country (2019-2030)

Figure 38. Mexico Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Brazil Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Middle East & Africa Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Ibritumomab Tiuxetan Market Share by Country (2019-2030)

Figure 42. Turkey Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Saudi Arabia Ibritumomab Tiuxetan Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. CASI Pharmaceuticals Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 45. Biogen Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 46. Bayer Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 47. Spectrum Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 48. CSL Behring Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 49. Grifols Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 50. Baxalta Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 51. Octapharma Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 52. Kedrion Revenue Growth Rate in Ibritumomab Tiuxetan Business (2019-2024)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

Figure 55. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Inotuzumab Ozogamicin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Rituxan Rituximab Monoclonal Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Ipilimumab Market Research Report 2024

Global Afutuzumab Market Research Report 2024

Blinatumomab Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Blinatumomab Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Rituximab Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Monoclonal Antibodies for Non small Cell Lung Cancer Market Research Report 2025

Bevacizumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antibody radionuclide Conjugates Market Research Report 2024

Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024

Global Rituximab Biosimilars Market Research Report 2025

Global Antibody Drugs Market Insights Forecast to 2030

Gemtuzumab Ozogamicin Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Gemtuzumab Ozogamicin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024

Rituxan Rituximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Rituxan Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions